Compare OHI & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OHI | ARWR |
|---|---|---|
| Founded | N/A | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0B | 12.4B |
| IPO Year | 2001 | 2009 |
| Metric | OHI | ARWR |
|---|---|---|
| Price | $45.66 | $56.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 15 |
| Target Price | $51.44 | ★ $107.36 |
| AVG Volume (30 Days) | 1.9M | ★ 2.0M |
| Earning Date | 11-03-2026 | 11-24-2026 |
| Dividend Yield | ★ 5.97% | N/A |
| EPS Growth | 25.16 | ★ 99.80 |
| EPS | ★ 1.66 | N/A |
| Revenue | ★ $1,190,099,000.00 | $16,142,321.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.48 | N/A |
| P/E Ratio | $27.42 | ★ N/A |
| Revenue Growth | ★ 13.19 | N/A |
| 52 Week Low | $39.26 | $36.73 |
| 52 Week High | $52.39 | $95.49 |
| Indicator | OHI | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 49.81 | 24.20 |
| Support Level | $45.17 | $54.02 |
| Resistance Level | $46.90 | $66.37 |
| Average True Range (ATR) | 0.81 | 2.14 |
| MACD | 0.09 | -0.02 |
| Stochastic Oscillator | 66.96 | 3.06 |
Omega Healthcare Investors Inc is a real estate investment trust that invests in healthcare-related real estate properties located in the United States (U.S.), the United Kingdom (U.K.), and Canada. The company's objective is to provide attractive returns to investors while serving as the preferred capital partner to its third-party healthcare operating companies and affiliates, as well as other third-party healthcare operators, allowing them to focus on delivering a high level of care to their resident patients. Omega's investment portfolio mainly consists of skilled nursing facilities, assisted living facilities (ALFs), including care homes in the U.K., independent living facilities, rehabilitation and acute care facilities, and continuing care retirement communities.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.